In collaboration with leading integrin drug developers, including Genentech, 7 Hills Pharma, and Pfizer, the 2nd Integrin-Targeted Drug Development Summit is designed for industry leaders to unite and outline clinical strategies for success, including patient selection biomarkers and dosing.
Get your critical questions answered to supercharge your clinical programs, direct your drug pipelines and ensure you take lessons learned to successfully modulate integrins to improve treatment regimens in chronic, familiar, and rare diseases.
Join us for this 3-day summit to gain unparalleled insights and experience first-hand from integrin drug developers to accelerate your candidate into the clinic and develop a first-in-class treatment option by modifying underlying disease biology for our patients.
Access the official agenda for more information.
Early bird & team discounts available – Secure your place today.
This post was originally published on Source Link